Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity.

BACKGROUND We studied the outcomes at school age in children who had participated in a double-blind, placebo-controlled trial of early postnatal dexamethasone therapy (initiated within 12 hours after birth) for the prevention of chronic lung disease of prematurity. METHODS Of the 262 children included in the initial study, 159 lived to school age. Of these children, 146 (72 in the dexamethasone group and 74 in the control group) were included in our study. All the infants had had severe respiratory distress syndrome requiring mechanical ventilation shortly after birth. In the dexamethasone group, 0.25 mg of dexamethasone per kilogram of body weight was given intravenously every 12 hours for one week, and then the dose was tapered. We evaluated the children's growth, neurologic and motor function, cognition, and school performance. RESULTS Children in the dexamethasone group were significantly shorter than the controls (P=0.03 for boys, P=0.01 for girls, and P=0.03 for all children) and had a significantly smaller head circumference (P=0.04). Children in the dexamethasone group had significantly poorer motor skills (P<0.001), motor coordination (P<0.001), and visual-motor integration (P=0.02). As compared with the controls, children in the dexamethasone group also had significantly lower full IQ scores (mean [+/-SD], 78.2+/-15.0 vs. 84.4+/-12.6; P=0.008), verbal IQ scores (84.1+/-13.2 vs. 88.4+/-11.8, P=0.04), and performance IQ scores (76.5+/-14.6 vs. 84.5+/-12.7, P=0.001). The frequency of clinically significant disabilities was higher among children in the dexamethasone group than among controls (28 of 72 [39 percent] vs. 16 of 74 [22 percent], P=0.04). CONCLUSIONS Early postnatal dexamethasone therapy should not be recommended for the routine prevention or treatment of chronic lung disease, because it leads to substantial adverse effects on neuromotor and cognitive function at school age.

[1]  K. E. Beery,et al.  Beery VMI : with supplemental developmental tests of visual perception and motor coordination and, Stepping stones age norms from birth to age six : administration, scoring, and teaching manual , 2004 .

[2]  T. Nettelbeck.  Mental retardation: Definition, classification, and systems of support , 2003 .

[3]  A. Bos,et al.  Treating Preterm Infants at Risk for Chronic Lung Disease with Dexamethasone Leads to an Impaired Quality of General Movements , 2002, Neonatology.

[4]  R. Luciano,et al.  A three year follow up of preterm infants after moderately early treatment with dexamethasone , 2002, Archives of disease in childhood. Fetal and neonatal edition.

[5]  Robert L. Schalock,et al.  Mental Retardation: Definition, Classification, and Systems of Supports. 10th Edition. , 2002 .

[6]  R. Luciano,et al.  Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. , 2002, Pediatrics.

[7]  J. Penrice,et al.  Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease , 2002, Archives of disease in childhood. Fetal and neonatal edition.

[8]  R. Ehrenkranz,et al.  Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[9]  K. Barrington.  The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs , 2001, BMC pediatrics.

[10]  F A Jolesz,et al.  Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. , 2001, Pediatrics.

[11]  W. Poole,et al.  Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. , 2001, The New England journal of medicine.

[12]  R. Ehrenkranz,et al.  Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[13]  R. Ehrenkranz,et al.  Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[14]  A. Zaritsky,et al.  Early postnatal dexamethasone treatment and increased incidence of cerebral palsy , 2000, Archives of disease in childhood. Fetal and neonatal edition.

[15]  D. J. Goldstein,et al.  Randomized Placebo-controlled Trial of a 42-Day Tapering Course of Dexamethasone to Reduce the Duration of Ventilator Dependency in Very Low Birth Weight Infants: Outcome of Study Participants at 1-Year Adjusted Age , 1999, Pediatrics.

[16]  T. Pauly,et al.  A Three-day Course of Dexamethasone Therapy to Prevent Chronic Lung Disease in Ventilated Neonates: A Randomized Trial , 1999, Pediatrics.

[17]  T. Yeh,et al.  Early dexamethasone therapy in preterm infants: a follow-up study. , 1998, Pediatrics.

[18]  T. Yeh,et al.  Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. , 1997, Pediatrics.

[19]  S. Atkinson,et al.  Longitudinal assessment of growth and bone mineral accretion in prematurely born infants treated for chronic lung disease with dexamethasone. , 1997, Early human development.

[20]  R. Pildes,et al.  A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. , 1996, Pediatrics.

[21]  D. Elbourne,et al.  Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. , 1995, Pediatrics.

[22]  A. Gibson,et al.  Growth retardation after dexamethasone administration: assessment by knemometry. , 1993, Archives of disease in childhood.

[23]  D. J. Goldstein,et al.  Follow-up of preterm infants treated with dexamethasone for chronic lung disease. , 1993, American journal of diseases of children.

[24]  E. Goldson,et al.  Eight-year school performance, neurodevelopmental, and growth outcome of neonates with bronchopulmonary dysplasia: a comparative study. , 1992, Pediatrics.

[25]  R. Mayer.  Thinking, problem solving, cognition, 2nd ed. , 1992 .

[26]  D. Aram,et al.  Effect of very low birth weight and subnormal head size on cognitive abilities at school age. , 1991, The New England journal of medicine.

[27]  P Szatmari,et al.  Cognitive abilities and school performance of extremely low birth weight children and matched term control children at age 8 years: a regional study. , 1991, The Journal of pediatrics.

[28]  J. Cummings,et al.  A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. , 1989, The New England journal of medicine.

[29]  D. S. Brudno,et al.  Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. , 1985, Pediatrics.

[30]  T. Thompson,et al.  CONTROLLED TRIAL OF DEXAMETHASONE THERAPY IN INFANTS WITH BRONCHOPULMONARY DYSPLASIA , 1983, The Lancet.

[31]  R. Mayer.  Thinking, Problem Solving, Cognition , 1983 .

[32]  M. Weichsel.  The therapeutic use of glucocorticoid hormones in the perinatal period: Potential neurological hazards , 1977, Annals of neurology.

[33]  M. Weichsel.  Glucocorticoid Effect upon Thymidine Kinase in the Developing Cerebellum , 1974, Pediatric Research.

[34]  A. Johnson,et al.  EFFECTS OF CORTICOSTEROIDS ON THE BIOCHEMICAL MATURATION OF RAT BRAIN: POSTNATAL CELL FORMATION , 1972, Journal of neurochemistry.